Changchun, China – A new study published in the journal eGastroenterology provides an updated assessment of the diagnosis, pathophysiology, and treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI). This severe and often fatal condition can occur in patients with cirrhosis. HRS-AKI is a functional and progressive kidney failure that is potentially...
treatment News
Wilson’s disease is a rare disorder of copper metabolism, an “orphan disease” – a condition so uncommon that its diagnosis and treatment had been neglected. The disease was recognised by the British neurologist Kinnear Wilson in 1912, but a simple means of detecting it did not exist until the 1950s,...
CAMBRIDGE, Mass. — Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending by consensus the approval of the high dose regimen of nusinersen for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA...
Los Angeles, Calif. – A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy (SABR) concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell...
HANGZHOU, China — HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today it has completed its Phase 1a study of HF1K16. Treating patients having multiple tumor types, the data demonstrated that the drug, administered as a single agent, is well-tolerated with only one dose-limiting...
SHENZHEN, China & ROCKVILLE, Md. – HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that the first patient has been dosed in HighTide’s Phase 2 PRONTO-PBC study evaluating first-in-class HTD1801 in adult...
SAN DIEGO – Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”), a clinical-stage biopharmaceutical company focused on developing oral therapies enabling the therapeutic use of low dose carbon monoxide (CO), today announced that the company has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) permitting the company to...
EB Research Partnership (“EBRP”) invested in the work that led to ZEVASKYN at Stanford University under their pioneering Venture Philanthropy Model. This approval marks a historic moment for the EB community as the third FDA approved treatment and the first autologous, cell-based gene therapy for RDEB (Recessive Dystrophic Epidermolysis Bullosa). NEW YORK,...
Plymouth, England – Drugs developed to combat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours. Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, Ritonavir and...
KING OF PRUSSIA, Pa. – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension...